Brexanolone, an intravenous allopregnanolone preparation

What it acts on

1. In two multicentre double-blind randomised placebo-controlled phase 3 trials of brexanolone injection in women with post-partum depression, the least-squares mean reduction in Hamilton Rating Scale for Depression total score at 60 hours was significantly greater with brexanolone than with placebo, the treatment was generally well tolerated and the most common adverse events included headache, dizziness and somnolence, with sedation-related events leading to dose interruption or reduction in a small number of patients.

   Brexanolone, an intravenous allopregnanolone preparation → Hamilton Rating Scale for Depression total score source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/gaba-research/30177236.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb", "start_char": 0, "end_char": 4369, "text_sha256": "e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb"}

   experimental_model

   Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion

   exposure

   Brexanolone, an intravenous formulation of the endogenous neurosteroid allopregnanolone, in severe and moderate postpartum depression

   limitations

   Two randomised trials with a depression rating scale as the endpoint over 60 hours of infusion, in a hospital setting.

   nutrient_topic

   GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. · Gamma-aminobutyric acid

   organism

   Human

   plain_language

   An infusion of the body own calming steroid lifted depression scores within sixty hours.

   primary_references

   [gb-p30177236] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018). https://pubmed.ncbi.nlm.nih.gov/30177236/ DOI: 10.1016/s0140-6736(18)31551-4

   tissue_or_cell_type

   Central nervous system

   GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22) · lines 313–324

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion · source_derived_draft · unverified_draft

   ### gb-a-neurosteroid-works-in-postpartum-depression In two multicentre double-blind randomised placebo-controlled phase 3 trials of brexanolone injection in women with post-partum depression, the least-squares mean reduction in Hamilton Rating Scale for Depression total score at 60 hours was significantly greater with brexanolone than with placebo, the treatment was generally well tolerated and the most common adverse events included headache, dizziness and somnolence, with sedation-related events leading to dose interruption or reduction in a small number of patients. Condition category: normal nutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in. plain_language: An infusion of the body own calming steroid lifted depression scores within sixty hours. organism: Human tissue_or_cell_type: Central nervous system experimental_model: Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion limitations: Two randomised trials with a depression rating scale as the endpoint over 60 hours of infusion, in a hospital setting. exposure: Brexanolone, an intravenous formulation of the endogenous neurosteroid allopregnanolone, in severe and moderate postpartum depression evidence_span: {"source_cache": "artifacts/gaba-research/30177236.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb", "start_char": 0, "end_char": 4369, "text_sha256": "e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb"} [gb-p30177236] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018). https://pubmed.ncbi.nlm.nih.gov/30177236/ DOI: 10.1016/s0140-6736(18)31551-4

   Complete structured claim and evidence